CL2013001684A1 - Composicion farmaceutica de administracion oral que comprende alisporivir, un componente lipofilico, un tensoactivo y un componente hidrofilico. - Google Patents
Composicion farmaceutica de administracion oral que comprende alisporivir, un componente lipofilico, un tensoactivo y un componente hidrofilico.Info
- Publication number
- CL2013001684A1 CL2013001684A1 CL2013001684A CL2013001684A CL2013001684A1 CL 2013001684 A1 CL2013001684 A1 CL 2013001684A1 CL 2013001684 A CL2013001684 A CL 2013001684A CL 2013001684 A CL2013001684 A CL 2013001684A CL 2013001684 A1 CL2013001684 A1 CL 2013001684A1
- Authority
- CL
- Chile
- Prior art keywords
- component
- alisporivir
- surfactant
- pharmaceutical composition
- oral administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42249910P | 2010-12-13 | 2010-12-13 | |
| IB2011000319 | 2011-02-18 | ||
| IB2011000653 | 2011-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013001684A1 true CL2013001684A1 (es) | 2014-01-10 |
Family
ID=45346477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013001684A CL2013001684A1 (es) | 2010-12-13 | 2013-06-12 | Composicion farmaceutica de administracion oral que comprende alisporivir, un componente lipofilico, un tensoactivo y un componente hidrofilico. |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20140005123A1 (es) |
| EP (1) | EP2651396B1 (es) |
| JP (2) | JP6259288B2 (es) |
| KR (1) | KR101928589B1 (es) |
| CN (2) | CN103282022A (es) |
| AR (1) | AR084235A1 (es) |
| AU (3) | AU2011344331A1 (es) |
| BR (1) | BR112013014606A2 (es) |
| CA (1) | CA2819167C (es) |
| CL (1) | CL2013001684A1 (es) |
| CO (1) | CO6761388A2 (es) |
| CY (1) | CY1119468T1 (es) |
| DK (1) | DK2651396T3 (es) |
| EC (1) | ECSP13012679A (es) |
| ES (1) | ES2643135T3 (es) |
| HR (1) | HRP20171485T1 (es) |
| HU (1) | HUE036784T2 (es) |
| IL (1) | IL226554A (es) |
| JO (1) | JO3337B1 (es) |
| LT (1) | LT2651396T (es) |
| MA (1) | MA34709B1 (es) |
| MX (1) | MX351667B (es) |
| MY (1) | MY165088A (es) |
| NZ (1) | NZ610950A (es) |
| PE (1) | PE20140104A1 (es) |
| PL (1) | PL2651396T3 (es) |
| PT (1) | PT2651396T (es) |
| RU (1) | RU2639482C2 (es) |
| SG (2) | SG190894A1 (es) |
| SI (1) | SI2651396T1 (es) |
| TW (1) | TWI599368B (es) |
| WO (1) | WO2012080176A2 (es) |
| ZA (1) | ZA201303721B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3337B1 (ar) | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
| WO2012082689A1 (en) | 2010-12-13 | 2012-06-21 | Array Biopharma Inc. | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS |
| WO2015008223A1 (en) | 2013-07-17 | 2015-01-22 | Novartis Ag | Treatment of hepatitis c virus infection with alisporivir and ribavirin |
| WO2015136455A1 (en) | 2014-03-13 | 2015-09-17 | Novartis Ag | New treatments of hepatitis c virus infection |
| AR114930A1 (es) * | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1274354A (fr) | 1956-03-10 | 1961-10-27 | Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol | |
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
| FR2697040B1 (fr) | 1992-10-21 | 1994-12-30 | Ind Entreprise | Elément de protection contre le bruit et son utilisation. |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| SE504582C2 (sv) * | 1995-07-06 | 1997-03-10 | Gs Dev Ab | Cyklosporinkomposition baserad på en L2-fas |
| ID25908A (id) | 1998-03-06 | 2000-11-09 | Novartis Ag | Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida |
| AU3843999A (en) * | 1998-05-07 | 1999-11-23 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
| DK1091975T3 (da) * | 1998-07-01 | 2006-04-18 | Debiopharm Sa | Ny cyclosporin med forbedret aktivitetsprofil |
| GB9903547D0 (en) * | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
| GB0001928D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| US6979672B2 (en) * | 2002-12-20 | 2005-12-27 | Polichem, S.A. | Cyclosporin-based pharmaceutical compositions |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| DK1793844T3 (da) * | 2004-10-01 | 2011-03-21 | Debiopharm Sa | Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion |
| EP1830871A1 (en) | 2004-12-23 | 2007-09-12 | Novartis AG | Compositions for hcv treatment |
| GB0504950D0 (en) | 2005-03-10 | 2005-04-20 | Novartis Ag | Organic compositions |
| US8501683B2 (en) | 2008-11-06 | 2013-08-06 | Debio Recherche Pharmaceutique S.A. | Cycloundecadepsipeptide compounds and use of said compounds as a medicament |
| JO3337B1 (ar) | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
-
2011
- 2011-12-11 JO JOP/2011/0373A patent/JO3337B1/ar active
- 2011-12-12 PL PL11794739T patent/PL2651396T3/pl unknown
- 2011-12-12 AU AU2011344331A patent/AU2011344331A1/en not_active Abandoned
- 2011-12-12 MX MX2013006525A patent/MX351667B/es active IP Right Grant
- 2011-12-12 CN CN2011800598202A patent/CN103282022A/zh active Pending
- 2011-12-12 KR KR1020137018234A patent/KR101928589B1/ko active IP Right Grant
- 2011-12-12 CN CN201510548088.5A patent/CN105125489B/zh not_active Expired - Fee Related
- 2011-12-12 SG SG2013040712A patent/SG190894A1/en unknown
- 2011-12-12 DK DK11794739.0T patent/DK2651396T3/en active
- 2011-12-12 BR BR112013014606A patent/BR112013014606A2/pt not_active Application Discontinuation
- 2011-12-12 JP JP2013543687A patent/JP6259288B2/ja not_active Expired - Fee Related
- 2011-12-12 PT PT117947390T patent/PT2651396T/pt unknown
- 2011-12-12 AR ARP110104622A patent/AR084235A1/es unknown
- 2011-12-12 CA CA2819167A patent/CA2819167C/en not_active Expired - Fee Related
- 2011-12-12 SI SI201131314T patent/SI2651396T1/sl unknown
- 2011-12-12 NZ NZ610950A patent/NZ610950A/en not_active IP Right Cessation
- 2011-12-12 SG SG10201509833YA patent/SG10201509833YA/en unknown
- 2011-12-12 TW TW100145812A patent/TWI599368B/zh not_active IP Right Cessation
- 2011-12-12 LT LTEP11794739.0T patent/LT2651396T/lt unknown
- 2011-12-12 RU RU2013132543A patent/RU2639482C2/ru not_active IP Right Cessation
- 2011-12-12 MY MYPI2013001865A patent/MY165088A/en unknown
- 2011-12-12 HU HUE11794739A patent/HUE036784T2/hu unknown
- 2011-12-12 EP EP11794739.0A patent/EP2651396B1/en active Active
- 2011-12-12 ES ES11794739.0T patent/ES2643135T3/es active Active
- 2011-12-12 US US13/992,948 patent/US20140005123A1/en not_active Abandoned
- 2011-12-12 PE PE2013001400A patent/PE20140104A1/es active IP Right Grant
- 2011-12-12 WO PCT/EP2011/072463 patent/WO2012080176A2/en active Application Filing
-
2013
- 2013-05-22 ZA ZA2013/03721A patent/ZA201303721B/en unknown
- 2013-05-23 IL IL226554A patent/IL226554A/en active IP Right Grant
- 2013-06-05 MA MA35960A patent/MA34709B1/fr unknown
- 2013-06-12 CL CL2013001684A patent/CL2013001684A1/es unknown
- 2013-06-13 EC ECSP13012679 patent/ECSP13012679A/es unknown
- 2013-06-14 CO CO13142692A patent/CO6761388A2/es unknown
-
2016
- 2016-02-19 AU AU2016201053A patent/AU2016201053B2/en not_active Ceased
- 2016-05-12 US US15/153,035 patent/US10188696B2/en not_active Expired - Fee Related
-
2017
- 2017-08-24 JP JP2017161652A patent/JP2018027949A/ja active Pending
- 2017-10-04 HR HRP20171485TT patent/HRP20171485T1/hr unknown
- 2017-10-09 AU AU2017245296A patent/AU2017245296A1/en not_active Abandoned
- 2017-10-12 CY CY20171101068T patent/CY1119468T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2017023I1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη, και μεθειονινη | |
| BRPI1008498A2 (pt) | Composto, prodroga do composto, medicamento, e, uso de um composto. | |
| BRPI1012892A2 (pt) | composto, e, composição farmacêutica. | |
| DK3984528T3 (da) | Farmaceutiske sammensætninger, som omfatter nilotinib | |
| BRPI1007018A2 (pt) | composto, composição farmacêutica, e , uso de um composto. | |
| BR112013016772A2 (pt) | composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado | |
| BRPI0917358A2 (pt) | formulação farmacêutica de liberação controlada e método. | |
| CL2013001942A1 (es) | Composicion de suministro de farmaco biodegradable que comprende a) un copolimero de tres bloques biodegradable, b) un copolimero de dos bloques biodegradable, y c) cuando menos un principio farmaceuticamente activo; metodo para su preparacion: y su uso. | |
| BRPI0918652A2 (pt) | Composições farmacêuticas e métodos de libração relacionadas. | |
| BRPI1008906A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
| BRPI0916877A2 (pt) | composição farmacêutica e administração da mesma | |
| BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0906556A2 (pt) | Composto, e, composição farmacêutica | |
| DK2381988T3 (da) | Medikamentadministrationsanordning | |
| DK2464342T3 (da) | Farmaceutisk formulering mod stofmisbrug | |
| BRPI0916689A2 (pt) | composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida. | |
| CL2014000844A1 (es) | Formulacion farmaceutica oral de liberacion prolongada en forma de multiparticulas, que comprende a) 40-o-(2-hidroxi)etil-rapamicina y b) al menos un recubrimiento de liberacion prolongada. | |
| BRPI0818680A2 (pt) | composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica | |
| BRPI0910072A2 (pt) | composto, composição farmaceutic, e, método para prover anestesia a um mamífero. | |
| BR112012003800A2 (pt) | composição, peptídeo, e formulação farmacêutica. | |
| BRPI0807078A2 (pt) | Composto, e, formulação farmacêutica | |
| BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
| BRPI0921654A2 (pt) | formulação farmacêutica | |
| BRPI1009392A2 (pt) | "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." | |
| BRPI1007484A2 (pt) | composição farmacêutica para administração oral |